Clorox Co (CLX) Stake Lessened by Federated Investors Inc. PA

Federated Investors Inc. PA lessened its stake in shares of Clorox Co (NYSE:CLX) by 16.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,838 shares of the company’s stock after selling 367 shares during the quarter. Federated Investors Inc. PA’s holdings in Clorox were worth $276,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in CLX. Csenge Advisory Group purchased a new position in shares of Clorox in the third quarter worth approximately $100,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new stake in Clorox during the 3rd quarter worth approximately $130,000. Ancora Advisors LLC bought a new stake in Clorox during the 3rd quarter worth approximately $135,000. Legacy Advisors LLC bought a new stake in Clorox during the 3rd quarter worth approximately $150,000. Finally, Cutler Group LP bought a new stake in Clorox during the 3rd quarter worth approximately $162,000. 77.73% of the stock is currently owned by hedge funds and other institutional investors.

In other news, COO Dawn C. Willoughby sold 54,205 shares of Clorox stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $157.39, for a total transaction of $8,531,324.95. Following the sale, the chief operating officer now owns 37,044 shares in the company, valued at $5,830,355.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Benno O. Dorer sold 152,449 shares of Clorox stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $164.83, for a total transaction of $25,128,168.67. Following the sale, the chief executive officer now owns 111,735 shares in the company, valued at approximately $18,417,280.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 313,228 shares of company stock worth $50,910,506. Company insiders own 1.40% of the company’s stock.

Clorox stock opened at $151.14 on Wednesday. The company has a market cap of $19.54 billion, a PE ratio of 24.14, a P/E/G ratio of 3.76 and a beta of 0.39. The company has a current ratio of 1.07, a quick ratio of 0.65 and a debt-to-equity ratio of 3.38. Clorox Co has a 1 year low of $113.57 and a 1 year high of $167.70.

Clorox (NYSE:CLX) last released its quarterly earnings data on Wednesday, October 31st. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.03. The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.53 billion. Clorox had a net margin of 13.59% and a return on equity of 102.65%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 earnings per share. As a group, analysts anticipate that Clorox Co will post 6.31 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 8th. Stockholders of record on Wednesday, January 23rd will be given a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Tuesday, January 22nd. Clorox’s payout ratio is currently 61.34%.

CLX has been the topic of a number of recent analyst reports. Atlantic Securities initiated coverage on shares of Clorox in a research note on Thursday, September 20th. They set a “neutral” rating and a $151.00 target price on the stock. Citigroup raised their target price on shares of Clorox from $153.00 to $169.00 and gave the stock a “hold” rating in a research note on Tuesday, November 20th. Barclays set a $138.00 target price on shares of Clorox and gave the stock a “hold” rating in a research note on Thursday, November 1st. Zacks Investment Research cut shares of Clorox from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Finally, Deutsche Bank raised their target price on shares of Clorox from $123.00 to $124.00 and gave the stock a “sell” rating in a research note on Thursday, November 1st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $148.08.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thestockobserver.com/2019/01/09/clorox-co-clx-stake-lessened-by-federated-investors-inc-pa.html.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply